Prime Capital Investment Advisors LLC Acquires 1,249 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Prime Capital Investment Advisors LLC boosted its holdings in Krystal Biotech, Inc. (NASDAQ:KRYS) by 93.1% in the third quarter, Holdings Channel reports. The firm owned 2,591 shares of the company’s stock after purchasing an additional 1,249 shares during the quarter. Prime Capital Investment Advisors LLC’s holdings in Krystal Biotech were worth $472,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Jamison Private Wealth Management Inc. acquired a new position in shares of Krystal Biotech during the 2nd quarter worth approximately $28,000. GAMMA Investing LLC increased its holdings in Krystal Biotech by 160.3% during the second quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock worth $28,000 after buying an additional 93 shares during the last quarter. Key Financial Inc acquired a new position in Krystal Biotech during the second quarter worth $28,000. Blue Trust Inc. raised its position in Krystal Biotech by 2,328.6% during the second quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after acquiring an additional 163 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new stake in Krystal Biotech in the third quarter valued at $53,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently weighed in on KRYS. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research note on Friday, August 30th. Chardan Capital upped their price objective on Krystal Biotech from $153.00 to $208.00 and gave the company a “buy” rating in a research note on Monday, August 5th. HC Wainwright reiterated a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research note on Tuesday, November 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Krystal Biotech in a report on Thursday, August 29th. Finally, Evercore ISI lifted their price objective on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a research report on Monday, August 12th. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $197.00.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now directly owns 1,500,882 shares in the company, valued at approximately $296,814,424.32. This represents a 1.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 14.10% of the company’s stock.

Krystal Biotech Price Performance

Shares of NASDAQ KRYS opened at $170.74 on Friday. The firm has a market cap of $4.91 billion, a price-to-earnings ratio of 96.46 and a beta of 0.82. The stock’s fifty day moving average price is $180.83 and its two-hundred day moving average price is $181.44. Krystal Biotech, Inc. has a one year low of $96.73 and a one year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The business had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. During the same period in the prior year, the company posted ($0.67) earnings per share. Krystal Biotech’s revenue was up 879.9% compared to the same quarter last year. On average, equities analysts anticipate that Krystal Biotech, Inc. will post 2.97 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).